StockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)

Investment analysts at StockNews.com started coverage on shares of Athersys (NASDAQ:ATHXGet Free Report) in a report released on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Athersys stock opened at $0.02 on Thursday. Athersys has a 12-month low of $0.01 and a 12-month high of $1.99. The firm’s fifty day moving average is $0.02 and its 200 day moving average is $0.20. The company has a market capitalization of $1.02 million, a PE ratio of -0.01 and a beta of -0.90.

Athersys (NASDAQ:ATHXGet Free Report) last announced its quarterly earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.15) EPS for the quarter.

Hedge Funds Weigh In On Athersys

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Athersys by 9.0% during the first quarter. Vanguard Group Inc. now owns 10,986,945 shares of the biopharmaceutical company’s stock valued at $6,652,000 after purchasing an additional 910,501 shares during the last quarter. State Street Corp lifted its holdings in shares of Athersys by 5.6% in the first quarter. State Street Corp now owns 3,781,384 shares of the biopharmaceutical company’s stock worth $2,290,000 after buying an additional 201,070 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Athersys by 37.6% in the second quarter. JPMorgan Chase & Co. now owns 3,155,103 shares of the biopharmaceutical company’s stock worth $820,000 after buying an additional 861,475 shares in the last quarter. Millennium Management LLC raised its stake in Athersys by 381.8% in the second quarter. Millennium Management LLC now owns 2,317,856 shares of the biopharmaceutical company’s stock valued at $603,000 after purchasing an additional 1,836,746 shares in the last quarter. Finally, UBS Group AG raised its stake in Athersys by 30.1% in the second quarter. UBS Group AG now owns 724,652 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 167,756 shares in the last quarter. Institutional investors own 19.35% of the company’s stock.

Athersys Company Profile

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.